Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
jan.lycke@gu.se
+46 31-342 9047
0733-109149

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg


Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn et al.
JAMA Neurology, Journal article 2020
Journal article

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova et al.
Scientific reports, Journal article 2019
Journal article

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen et al.
JAMA neurology, Journal article 2019
Journal article

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

Showing 61 - 70 of 73

2011

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Carolina Holmén, Fredrik Piehl, Jan Hillert, Anna Fogdell-Hahn, Malin Lundkvist et al.
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2011
Journal article

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle et al.
Annals of neurology, Journal article 2011
Journal article

2010

Leukocyte myeloperoxidase and pathogenesis of the post-polio syndrome
Charlotta Movitz, Tomas Bergström, Kristian Borg, Kristoffer Hellstrand, Erik Lycke et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, Journal article 2010
Journal article

2009

Allmän neurologi och multipel skleros
Jan Lycke, Mats Elm
Neurologi. Läkemedelsboken 2009-2010, Apoteket AB, Chapter in book 2009
Chapter in book

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Niklas Mattsson, M Axelsson, Sara Haghighi, Clas Malmeström, G Wu et al.
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2009
Journal article

2008

2006

Showing 61 - 70 of 73

Page Manager: Katinka Almrén|Last update: 9/1/2015
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://neurophys.gu.se/english/departments/clinical_neuroscience_and_rehabilitation/about-us/staff/?publicationPageNumber=7&selectedTab=2&languageId=100001&disableRedirect=true&returnUrl=http%3A%2F%2Fneurophys.gu.se%2Fsektioner%2Fklinisk-neurovetenskap%2Fom-sektionen%2Fpersonal%2F%3FpublicationPageNumber%3D2%26selectedTab%3D2%26languageId%3D100000%26print%3Dtrue%26userId%3Dxlycja&userId=xlycja
Utskriftsdatum: 2020-03-31